KORU Medical Systems Inc

KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

KORU Medical Systems reports robust Q4 growth and eyes international expansion

KORU Medical Systems demonstrated strong financial performance in Q4 2022, with revenue growth and cash position exceeding expectations.
The company's strategic focus on novel therapies and international expansion presents growth opportunities, though margin improvement and market challenges remain.
With a clear Vision 26 strategy and positive revenue guidance for 2023, KORU is poised for continued growth and market leadership.

KORU Medical Systems excels in Q1 2023, poised for strategic growth

KORU Medical Systems delivered a robust performance in Q1 2023, showcasing growth across key business segments and strategic initiatives.
The company's focus on revenue targets, margin improvement, and operational efficiency positions it well for future success.
While challenges like managing cash burn and market dynamics exist, KORU's strengths in product leadership and financial management offer resilience.
Strategic opportunities in market expansion, innovation, and customer value creation provide a positive outlook for the company's growth trajectory.

KORU Medical Systems reports Q2 growth, projects improved margins

KORU Medical Systems demonstrated overall growth in Q2 2023, driven by strong performance in core businesses and improving gross margins. While facing challenges in Novel Therapies and a net cash operating loss, the company remains optimistic about future revenue growth and strategic initiatives.

KORU Medical Systems Inc reports Q3 revenue decline, focuses on margin expansion and Novel Therapies collaborations

KORU Medical Systems Inc faces revenue challenges but focuses on margin expansion, expense control, and strategic investments. The company aims for cash flow breakeven by Q4 2024, emphasizing Novel Therapies business and market growth assumptions.

KORU Medical Systems reports solid Q4 growth and outlines expansion plans for 2024

KORU Medical Systems' Q4 2023 performance reflects steady growth and strategic advancements in product development and market expansion. While facing challenges in production efficiency and European certification, the company is well-positioned to capitalize on opportunities in prefilled syringes and novel therapies for future growth.

KORU Medical Systems achieves record revenue and eyes global expansion

KORU Medical Systems delivered strong Q1 2024 results with record revenue and gross margin, alongside reduced cash burn.
The company reaffirmed guidance, secured new collaborations, and expanded internationally, while facing regulatory approval challenges.
Opportunities lie in FDA approvals, cash flow targets, and sustained U.S. core business growth through innovations and partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the first quarter ended March 31, 2023. Highlights: First quarter net revenue growth versus prior year of 18% to $7.4 million, marking the sixth conse.

KORU Medical Systems, Inc. Announces 2023 First Quarter Financial Results

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will report first quarter 2023 financial results on Thursday, May 4, 2023. KORU Medical's management will host a conference call and webcast at 4:30 p.m.

KORU Medical Systems to Report First Quarter Financial Results on May 4, 2023

KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Hannah Jeffrey - Investor Relations Linda Tharby - President and Chief Executive Officer Tom Adams - Interim Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Caitlin Cronin - Canaccord Genuity Joe Downing - Piper Sandler Operator Greetings and welcome to KORU Medical Systems Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

KORU Medical Systems, Inc. (KRMD) Q4 2022 Earnings Call Transcript

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 20% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

KORU Medical Systems Inc. (KRMD) Reports Q4 Loss, Misses Revenue Estimates

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today reported financial results for the fourth quarter and full year ended December 31, 2022. The Company also issued guidance for the full year 2023.

KORU Medical Systems Announces 2022 Q4 and Full Year Financial Results, Accelerating to 19% Revenue Growth in 2022

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will report fourth quarter and full year 2022 financial results on Wednesday, March 8, 2023.

KORU Medical Systems to Report Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023

MAHWAH, N.J.--( BUSINESS WIRE )--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced a development agreement with a pharmaceutical manufacturer of subcutaneous immunoglobulin therapy (SCIg) to develop and seek regulatory approval of the Freedom Infusion System with an SCIg prefilled syringe.

KORU Medical Systems Announces Subcutaneous Immunoglobulin Prefilled Syringe Development Agreement

Asure Software

KORU Medical Systems (KRMD), Asure Software (ASUR) and YPF Sociedad Anonima (YPF) have been selected as the breakout stocks for today.

3 Best Breakout Stocks to Invest In Ahead of 2023

MAHWAH, N.J.--( BUSINESS WIRE )--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use subcutaneous drug delivery systems that improve quality of life for patients, today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference on December 1st, 2022.

KORU Medical Systems to Participate in the Piper Sandler 34th Annual Healthcare Conference

KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Hannah Jeffrey - The Gilmartin Group Linda Tharby - President and CEO Tom Adams - Interim Chief Financial Officer Josh Bennett - VP of Strategy and Business Development Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Caitlin Cronin - Canaccord Genuity Joseph Downing - Piper Sandler Operator Greetings, and welcome to KORU Medical Systems Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

KORU Medical Systems, Inc. (KRMD) Q3 2022 Earnings Call Transcript

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 40% and 11.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

KORU Medical Systems Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates

KORU Medical Systems Announces 2022 Third Quarter Financial Results

KORU Medical Systems Announces Novel Therapy Collaboration for Three Indications with Kira Pharmaceuticals

KORU Medical Systems to Report Third Quarter 2022 Financial Results on November 9, 2022

KORU Medical Systems to Participate in Upcoming Industry Conferences

KORU Medical Systems Appoints Brent Rutland as Vice President of Medical Affairs

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced its membership in the Subcutaneous (SC) Drug Development & Delivery Consortium (the “Consortium”), making it one of the first device companies to be added to the Consortium. “The Consortium creates an important forum to identify and address key challenges and opportuni

KORU Medical Systems Joins Subcutaneous Drug Development & Delivery Consortium

KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Gregory Chodaczek - Gilmartin Group Linda Tharby - President, CEO & Director Tom Adams - Interim CFO and VP, Financial Planning & Analysis Conference Call Participants Connor Stevenson - Craig-Hallum Gibran Ahmed - Canaccord Jason Bednar - Piper Sandler & Co. Operator Greetings, and welcome to KORU Medical Systems Second Quarter 2022 Earnings Conference Call. [Operator Instructions].

KORU Medical Systems, Inc. (KRMD) CEO Linda Tharby on Q2 2022 Results - Earnings Call Transcript

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the company will participate in Canaccord Genuity's 42nd Annual Growth Conference on August 10th, 2022. KORU Medical's management is scheduled to present at the Canaccord Growth Conference on Wednesday, August 10th, 2022 at 10:00 AM ET. Interested parties c

KORU Medical Systems to Participate in Canaccord Genuity's 42nd Annual Growth Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the second quarter ended June 30, 2022. Highlights: Year-over-year net sales growth of 18.4% to $6.5 million, marking the third consecutive quarter of

KORU Medical Systems Announces 2022 Second Quarter Financial Results

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report second quarter 2022 financial results on Wednesday, August 3, 2022. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conferenc

KORU Medical Systems to Report Second Quarter 2022 Financial Results on August 3, 2022

Repro Med Systems, Inc. (NASDAQ:KRMD ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Greg Chodaczek - Managing Director Linda Tharby - President & CEO Karen Fisher - CFO, Treasurer & Corporate Secretary Conference Call Participants Chase Knickerbocker - Craig-Hallum Joseph Downing - Piper Sandler & Co. Operator Greetings, and welcome to KORU Medical Systems' First Quarter 2022 Earnings Conference Call. [Operator Instructions].

Repro Med Systems, Inc. (KRMD) CEO Linda Tharby on Q1 2022 Results - Earnings Call Transcript

Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 16.67% and 4.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Repro Med Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the first quarter ended March 31, 2022. Highlights: Year-over-year net sales growth of 15% to $6.2 million, marking the second

KORU Medical Systems Announces 2022 First Quarter Financial Results

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced 510k clearance for use of the KORU Medical FreedomEdge® infusion system to deliver pegcetacoplan 20 mL solution, branded as EMPAVELI® or Aspaveli® a

News for KORU Medical Systems Inc Stock (KRMD)